PD BRAC Cohorts

The PDBP BRAC is responsible for reviewing all requests for biospecimen access for PDBP as well as other cohorts.

Biospecimen Availability Overview

The table below provides an overview of what types of biospecimens are available in each cohort study.

Cohort Population Research Intent DNA RNA CSF Whole Blood Plasma Serum Urine
NINDS Parkinson's disease Biomarkers Program (PDBP) Early to advance PD and controls                
24-Hour Biofluid Sampling Early to moderate PD and controls Biomarker discovery              
BioFind Moderate to advanced PD and controls Biomarker discovery              
DATATOP Early, unmedicated PD Biomark discovery and validation              
FS-ZONE 217 individuals with early PD Phase II placebo-controlled study of the safety and effect of two dosages of oral pioglitazone              
Harvard Biomarker Study >600 early-stage, medicated and unmedicated cases with PD, >600 individuals with congnitive impairment, and >700 controls Discovery and validation of cross-sectional and longitudinal biomarkers for PD and AD              
LRRK2 Cohort Biomarker discovery Biomarker discovery              
STEADY-III 336 subjects with early idiopathic PD not requiring dopaminergic therapy Pharmacogenetics/pharmacodynamics              
SURE-PD3 298 Individuals with early Parkinson's Disease Pharmacogenetics/pharmacodynamics              
SURE-PD2 75 individuals with early Parkinson's Disease Pharmacogenetics/pharmacodynamics              

Interested in obtaining biosamples?

All investigators interested in obtaining biosamples must submit an online application for approval. All applications are submitted to the PD BRAC for review. Upon approval, an investigator is able to obtain biosamples.